Mucinase-engineered cell membrane nanovesicles degrade the glycocalyx shield to potentiate antitumor immunity
摘要
The tumor glycocalyx forms a protective shield that masks checkpoint proteins and compromises the efficacy of immunotherapies. While the bacterial protease StcE can degrade this barrier by cleaving O-glycosylated mucin domains, its therapeutic potential is hindered by off-target toxicity and high immunogenicity. To overcome these limitations, we developed a biomimetic platform of cell membrane fusion nanovesicles (FNVs) that co-display StcE and CD47 nanobodies (nCD47) for spatially controlled glycocalyx degradation and enhanced checkpoint blockade. Using the SpyTag/SpyCatcher system, we generated StcE-displaying NVs, which were then fused with nCD47-displaying NVs. The resulting StcE-nCD47-FNVs retained potent mucin-hydrolyzing activity and exhibited well-defined physicochemical properties. By removing the mucin barrier, StcE-nCD47-FNVs significantly enhanced nCD47 binding to CD47 on tumor cells, thereby potentiating antitumor immune responses. More importantly, benefiting from prolonged circulation of FNVs and tumor targeting of nCD47, the StcE-nCD47-FNVs platform demonstrated superior tumor accumulation and biosafety compared to free StcE. In murine models of colorectal and breast cancer, StcE-nCD47-FNVs significantly suppressed tumor growth and metastasis by remodeling the tumor microenvironment, as evidenced by increased M1 macrophage polarization and CD8⁺ T cell infiltration. By integrating glycocalyx engineering with vesicle nanotechnology, StcE-nCD47-FNVs offer a safe, robust, and versatile strategy to breach the tumor glycocalyx for next-generation cancer immunotherapy.
参考文献
1. K. Aliazis et al., The tumor microenvironment's role in the response to immune checkpoint blockade. Nat. Cancer 6, 924–937 (2025).
2. M. Y. Feng et al., Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568–586 (2019).
3. M. E. W. Logtenberg, F. A. Scheeren, T. N. Schumacher, The CD47-SIRPα immune checkpoint. Immunity 52, 742–752 (2020).
4. R. Upton et al., Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc. Natl. Acad. Sci. 118, e2026849118 (2021).
5. R. Advani et al., CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
6. C. R. Shurer et al., Physical principles of membrane shape regulation by the glycocalyx. Cell 177, 1757–1770 (2019).
7. J. C. H. Kuo, J. G. Gandhi, R. N. Zia, M. J. Paszek, Physical biology of the cancer cell glycocalyx. Nat. Phys. 14, 658–669 (2018).
8. A. P. Corfield, Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim. Biophys. Acta, Gen. Subj. 1850, 236–252 (2015).
9. L. Z. Mi et al., Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat. Struct. Mol. Biol. 18, 984–989 (2011).
10. D. Y. W. Lin et al., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. 105, 3011–3016 (2008).
11. G. Fenalti et al., Structure of the human marker of self 5-transmembrane receptor CD47. Nat. Commun. 12, 5218 (2021).
12. C. V. Rao et al., Small-molecule inhibition of GCNT3 disrupts mucin biosynthesis and malignant cellular behaviors in pancreatic cancer. Cancer Res. 76, 1965–1974 (2016).
13. K. Pedram et al., Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat. Biotechnol. 42, 597–607 (2024).
14. S. A. Malaker et al., The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc. Natl. Acad. Sci. 116, 7278–7287 (2019).
15. N. Villalba, S. Baby, S. Y. Yuan, The endothelial glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis. Frontiers in Cell and Developmental Biology 9, 711003 (2021).
16. R. L. Szabady, M. A. Lokuta, K. B. Walters, A. Huttenlocher, R. A. Welch, Modulation of neutrophil function by a secreted mucinase of escherichia coli O157:H7. PLoS Pathog. 5, e1000320 (2009).
17. G. van Niel, G. D'Angelo, G. Raposo, Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).
18. D. W. Greening et al., Clinical relevance of extracellular vesicles in cancer — therapeutic and diagnostic potential. Nat. Rev. Clin. Oncol. 22, 924–952 (2025).
19. X. Y. Lin, L. D. Yue, K. Cheng, L. Rao, Engineering cellular vesicles for immunotherapy. Acc. Mater. Res. 6, 327–339 (2025).
20. C. C. Zhao et al., Vesicular antibodies: shedding light on antibody therapeutics with cell membrane nanotechnology. Adv. Mater. 35, e2207875 (2023).
21. Y. Wen et al., Cell-derived nanovesicles prepared by membrane extrusion are good substitutes for natural extracellular vesicles. Extracell Vesicle 1, 100004 (2022).
22. G. Walsh, Biopharmaceutical benchmarks 2018. Nat. Biotechnol. 36, 1136–1145 (2018).
23. K. Lang, J. W. Chin, Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins. Chem. Rev. 114, 4764–4806 (2014).
24. J. C. Wu, H. L. Lu, X. M. Xu, L. Rao, Y. Ge, Engineered cellular vesicles displaying glycosylated nanobodies for cancer immunotherapy. Angew. Chem. Int. Ed. 63, e202404889 (2024).
25. B. Zakeri et al., Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. 109, 690–697 (2012).
26. G. Kim et al., Engineering modular enzyme assembly: synthetic interface strategies for natural products biosynthesis applications. Nat. Prod. Rep. 42, 1489–1506 (2025).
27. D. P. Arnold, Y. X. Xu, S. C. Takatori, Antibody binding reports spatial heterogeneities in cell membrane organization. Nat. Commun. 14, 2884 (2023).
28. M. A. Goyette et al., Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx- mediated resistance to HER2targeting therapies. Proc. Natl. Acad. Sci. 121, e2322688121 (2024).
29. Y. Zhou et al., T Cell-derived apoptotic extracellular vesicles hydrolyze cGAMP to alleviate radiation enteritis via surface enzyme ENPP1. Adv. Sci. 11, e2401634 (2024).
30. C. Kofoed et al., Programmable protein ligation on cell surfaces. Nature 645, 793–800 (2025).
31. S. B. Willingham et al., The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. 109, 6662–6667 (2012).
32. E. Rodríguez, S. T. T. Schetters, Y. van Kooyk, The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol. 18, 204–211 (2018).
33. S. Park et al., Immunoengineering can overcome the glycocalyx armour of cancer cells. Nat. Mater. 23, 429–438 (2024).
34. J. Lai et al., Triple Hybrid Cellular Nanovesicles Promote Cardiac Repair after Ischemic Reperfusion. ACS Nano 18, 4443–4455 (2024).
35. X. Xiong et al., Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles. J. Extracell. Vesicles 11, e12243 (2022).
36. L. Rao et al., Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nat. Commun. 11, 4909 (2020).
指标
DOI：
Submission ID：
下载次数
已发布
版本
- 2026-05-08 (2)
- 2025-11-19 (1)
如何引用
下载引用
利益冲突声明
作者声明无任何需要披露的利益冲突。
Copyright
本预印本的版权持有者为作者/资助方。
保留所有权利。本作品受版权保护。未经版权所有者事先书面许可，不得以任何形式或方式复制、分发或传播本作品的任何部分。